Defibrotide

Therapeutic indications

Defibrotide is indicated for:

Severe hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation (HSCT)

Population group: only minors (0 - 18 years old) , adults (18 years old or older)

Defibrotide is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.

It is indicated in adults and in adolescents, children and infants over 1 month of age.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Defibrotide is contraindicated in the following cases:

Concomitant use of thrombolytic therapy

at least one of
Thrombolytic therapy
Enzymes

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: DEFITELIO Concentrate for solution for infusion
Structured Product Labeling (SPL/PLR) 2016: DEFITELIO Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈